市场调查报告书
商品编码
1419650
诱导多能干细胞生产市场 - 按製程(手动、自动化)、产品和服务(消耗品和套件、仪器、服务)、应用(药物开发和发现、再生医学)、最终用途和全球预测,2024-2032 年Induced Pluripotent Stem Cells Production Market - By Process (Manual, Automated), Product & Service (Consumables & Kits, Instruments, Service), Application (Drug Development & Discovery, Regenerative Medicine), End-use, & Global Forecast, 2024-2032 |
由于再生医学研究和开发计画的不断升级,2023 年至 2032 年间,全球诱导多能干细胞生产市场将以 9.8% 的复合CAGR成长。研究机构和生物製药公司之间的合作正在加强,促进技术进步,并加速基于 iPSC 的治疗应用。随着学术界和工业界之间协同作用的加强,在利用 iPSC 潜力提供个人化医疗和再生疗法创新解决方案的共同努力的推动下,市场将大幅成长。
例如,2023 年,SCG Therapy 在新加坡开设了最先进的细胞疗法製造厂和研发中心。该工厂利用先进的细胞治疗製造和现成的人类诱导多能干细胞(iPSC)技术,旨在向亚太地区、欧洲和北美的合作医院提供细胞治疗产品,增强SCG在全球市场的能力。此举标誌着 SCG 对加强诱导多能干细胞生产产业、增强生产能力以满足全球需求和满足日益增长的患者需求做出了重大贡献。
诱导多能干细胞生产市场根据最终用途、应用和地区而分散。
在对 iPSC 创新研究和治疗应用的日益关注的推动下,研究和学术机构部门将在 2032 年建立重要的市场立足点。研究机构利用 iPSC 技术进行疾病建模、药物发现和再生医学研究,为市场的成长做出了重大贡献。随着干细胞研究合作和资金的激增,研究和学术机构部门将成为 iPSC 生产市场的关键驱动力。
由于 iPSC 在治疗各种疾病的再生疗法中的应用不断增加,到 2032 年,再生医学领域将大幅成长。随着再生医学因其在组织修復和器官再生方面的潜力而受到关注,iPSC 在推动这些创新治疗方法方面发挥关键作用。再生医学产业越来越关注基于 iPSC 的解决方案,这将使其成为市场扩张的关键贡献者。
由于欧洲对生物医学研究的强劲投资、有利的监管框架以及对再生医学的日益重视,欧洲诱导多能干细胞生产产业将在 2023 年和 2032 年实现显着的CAGR。欧洲国家对推动 iPSC 技术的临床应用做出了重大承诺,推动市场成长。凭藉蓬勃发展的生物技术格局和战略合作,欧洲将成为影响 iPSC 生产份额的关键贡献者。
Global Induced Pluripotent Stem Cells Production Market will grow at a 9.8% CAGR between 2023 and 2032, owing to the escalating research and development initiatives in regenerative medicine. Collaborations between research institutions and biopharmaceutical companies are intensifying, fostering technological advancements, and accelerating iPSC-based therapeutic applications. As the synergy between academia and industry strengthens, the market will witness substantial growth, propelled by the combined efforts to harness the potential of iPSCs for innovative solutions in personalized medicine and regenerative therapies.
For instance, in 2023, SCG Therapy inaugurated a state-of-the-art cell therapy manufacturing facility and R&D center in Singapore. Leveraging advanced cell therapy manufacturing and off-the-shelf human-induced pluripotent stem cell (iPSC) technology, the facility aims to supply cell therapy products to partner hospitals across Asia Pacific, Europe, and North America, enhancing SCG's capabilities in the global market. This move marks SCG's significant contribution to strengthening the induced pluripotent stem cells production industry, augmenting production capabilities to meet global demand and address increasing patient needs.
The induced pluripotent stem cells production market is fragmented based on end-use, application, and region.
The research and academic institutes segment will establish a significant market foothold by 2032, fueled by the increasing focus on iPSCs for innovative research and therapeutic applications. Research institutions leverage iPSC technology for disease modeling, drug discovery, and regenerative medicine studies, significantly contributing to the market's growth. With a surge in collaborations and funding for stem cell research, the research and academic institutes segment will stand as a key driver in the iPSC production market.
The regenerative medicine segment will witness a substantial upswing by 2032, attributed to the growing application of iPSCs in regenerative therapies for treating various medical conditions. As regenerative medicine gains traction for its potential in tissue repair and organ regeneration, iPSCs play a pivotal role in advancing these innovative therapeutic approaches. The regenerative medicine sector's increasing focus on iPSC-based solutions will position it as a key contributor to market expansion.
Europe induced pluripotent stem cells production industry will register a notable CAGR during 2023 and 2032 due to its robust investments in biomedical research, favorable regulatory frameworks, and an increasing emphasis on regenerative medicine. European countries exhibit a significant commitment to advancing iPSC technology for clinical applications, driving market growth. With a thriving biotechnology landscape and strategic collaborations, Europe will stand as a key contributor to shaping the share of iPSC production.